Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UK Accelerated Access Review Can Create A Post-Brexit 'Medtech Powerhouse'

Executive Summary

Medical technology stakeholders in the UK will be poring over the detail of the much-anticipated Accelerated Access Review (AAR), the final report of which was released Oct. 24. The initial response from the industry has been positive.

You may also be interested in...



Is The UK Still Open For Medtech Innovation And Reimbursement?

Confusing and ineffective channels of innovation adoption and a lack of funding hamper the UK's reputation as one of the world's health care capitals and a driver of care excellence – in spite of its global brands, NICE, MHRA and the NHS itself. But changes that should transform market access are in place and are worthy of close attention in the next two to three years.

UK Extols NHS Asset In The ‘No Plan B’ Post-Brexit World

The UK medtech industry is in a state of flux given the known unknowns of Brexit, perennial health-care funding pressures that will only exacerbate, and a menu of cost-saving initiatives that require medtech companies to adjust how they work with the National Health Service. Improving NHS and its role as a boon to smaller UK medtech companies is an important priority of industry.

Fees Should Be A Last Resort For NICE Funding, Says UK Medtechs

UK industry has given its rationale for opposing health technology assessment fees from NICE, but suggests that it might be prepared to discuss the general theme of NICE funding if the conditions were right.

Related Content

Topics

UsernamePublicRestriction

Register

MT103998

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel